

**TARO PHARMACEUTICALS NORTH AMERICA INC.****BALANCE SHEETS**

	<u>March 31, 2025</u>	<u>March 31, 2024</u>
	<u>U.S. Dollars</u>	
	<u>Unaudited</u>	
ASSETS		
CURRENT ASSETS:		
Cash and cash equivalents	\$ 5,140	\$ 27,792
Short-term bank deposits	-	-
Marketable securities	-	-
Other receivables and prepaid expenses:		
Prepaid expenses	-	-
Intercompany balances	-	-
Other	-	-
TOTAL Other receivables and prepaid expenses	<u>-</u>	<u>-</u>
TOTAL CURRENT ASSETS	5,140	27,792
LONG-TERM RECEIVABLES AND OTHER ASSETS	372,627,244	372,627,244
GOODWILL	-	-
INTANGIBLE ASSETS AND DEFERRED COSTS, NET	-	-
TOTAL ASSETS	<u>\$ 372,632,384</u>	<u>\$ 372,655,036</u>
LIABILITIES AND SHAREHOLDERS' EQUITY		
CURRENT LIABILITIES:		
Accounts payable:		
Trade payables	\$ -	\$ -
Other current liabilities:		
Intercompany balances	-	-
Accrued expenses	-	-
Other	-	-
TOTAL Other current liabilities	<u>-</u>	<u>-</u>
TOTAL CURRENT LIABILITIES	<u>-</u>	<u>-</u>
SHAREHOLDERS' EQUITY	372,632,384	372,655,036
	<u>\$ 372,632,384</u>	<u>\$ 372,655,036</u>

TARO PHARMACEUTICALS NORTH AMERICA INC.

STATEMENTS OF INCOME

	For the year Ended March 31, 2025	For the year Ended March 31, 2024
	U.S. Dollars	
	Unaudited	
Sales	\$ -	\$ -
Cost of sales	-	-
Gross profit	-	-
Research and development	-	-
Selling and marketing expenses	-	-
General and administrative expenses	22,652	-
Operating income	(22,652)	-
Financing income (expenses), net	-	-
Other income (expense)	-	-
Income before taxes on income	(22,652)	-
Taxes on income	-	-
Net income for the period before subsidiaries and dividend	(22,652)	-
Dividend income, net	-	-
Subsidiaries	-	-
Net income for the period	\$ (22,652)	\$ -

**TARO PHARMACEUTICALS NORTH AMERICA INC.**

**Changes in Shareholders' Equity**

U.S. Dollars

Unaudited

	Number of Shares	Share Capital	Additional Paid-in Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings	Total Taro Shareholders' Equity
Balance at March 31, 2021	3	3	3,511,728	-	369,150,819	372,662,550
Adjustment to Opening RE balance	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-
Comprehensive loss, net of tax	-	-	-	-	-	-
Net income	-	-	-	-	(825)	(12,229)
Balance at March 31, 2022	3	3	3,511,728	-	369,149,994	372,666,865
Adjustment to Opening RE balance	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-
Comprehensive income, net of tax	-	-	-	-	-	-
Net income	-	-	-	-	(6,689)	(6,689)
Balance at March 31, 2023	3	3	3,511,728	-	369,143,305	372,660,176
Adjustment to Opening RE balance	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-
Comprehensive income, net of tax	-	-	-	-	-	-
Net income	-	-	-	-	-	-
Balance at March 31, 2024	3	3	3,511,728	-	369,143,305	372,660,176
Adjustment to Opening RE balance	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-
Comprehensive income, net of tax	-	-	-	-	-	-
Net income	-	-	-	-	(22,652)	-
Balance at March 31, 2025	3	3	3,511,728	-	369,120,653	372,632,384